{
    "id": "6028ffae1cb411341a000106",
    "question": "Does erenumab target the calcitonin gene-related peptide?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"Erenumab is a monoclonal antibody used in the treatment of multiple sclerosis and migraines. To determine if erenumab targets the calcitonin gene-related peptide (CGRP), we need to understand the mechanism of action of erenumab. Erenumab works by targeting the calcitonin receptor receptor antagonist 1 (CALCR), which is involved in the regulation of calcitonin gene-related peptide (CGRP) levels. CGRP is a potent vasodilator involved in the pathophysiology of migraines. Therefore, by targeting CALCR, erenumab indirectly reduces CGRP levels, which leads to its therapeutic effects in migraine treatment. Hence, the correct answer is that erenumab does target the calcitonin gene-related peptide indirectly through its action on CALCR.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 13.060330390930176
}